Yayan Zhang

3.9k total citations
10 papers, 440 citations indexed

About

Yayan Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yayan Zhang has authored 10 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Yayan Zhang's work include Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Acute Myeloid Leukemia Research (2 papers). Yayan Zhang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Acute Myeloid Leukemia Research (2 papers). Yayan Zhang collaborates with scholars based in United States, Canada and Japan. Yayan Zhang's co-authors include Vincent Ribrag, Arun Balakumaran, Sabine Chlosta, Pier Luigi Zinzani, John Kuruvilla, Craig H. Moskowitz, Jean‐Marie Michot, Margaret A. Shipp, Philippe Armand and Guillermo Garcia‐Manero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Future Oncology.

In The Last Decade

Yayan Zhang

10 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yayan Zhang United States 7 331 148 142 78 65 10 440
Johannes Andel Austria 10 254 0.8× 98 0.7× 56 0.4× 94 1.2× 95 1.5× 30 429
Yi‐Fang Chang Taiwan 12 153 0.5× 115 0.8× 51 0.4× 65 0.8× 136 2.1× 33 402
Guillaume Manson France 10 369 1.1× 156 1.1× 148 1.0× 66 0.8× 41 0.6× 17 465
Yu‐Jing Zhang China 10 324 1.0× 161 1.1× 384 2.7× 52 0.7× 25 0.4× 20 450
Lokanatha Dasappa India 9 106 0.3× 47 0.3× 52 0.4× 40 0.5× 36 0.6× 41 257
Yuhua Feng China 13 130 0.4× 53 0.4× 114 0.8× 69 0.9× 208 3.2× 27 433
Scott D. Lunin United States 9 102 0.3× 84 0.6× 88 0.6× 48 0.6× 125 1.9× 21 297
Fernando Hurtado de Mendoza Peru 8 298 0.9× 23 0.2× 161 1.1× 84 1.1× 64 1.0× 16 401
Manuel F. Rosado United States 10 249 0.8× 87 0.6× 333 2.3× 63 0.8× 58 0.9× 14 491
Yuki Komabayashi Japan 8 227 0.7× 159 1.1× 156 1.1× 39 0.5× 65 1.0× 17 328

Countries citing papers authored by Yayan Zhang

Since Specialization
Citations

This map shows the geographic impact of Yayan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yayan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yayan Zhang more than expected).

Fields of papers citing papers by Yayan Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yayan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yayan Zhang. The network helps show where Yayan Zhang may publish in the future.

Co-authorship network of co-authors of Yayan Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Yayan Zhang. A scholar is included among the top collaborators of Yayan Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yayan Zhang. Yayan Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Motzer, Robert J., Manuela Schmidinger, Masatoshi Eto, et al.. (2023). LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncology. 19(2). 113–121. 25 indexed citations
3.
Garcia‐Manero, Guillermo, Vincent Ribrag, Yayan Zhang, et al.. (2022). Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. Leukemia & lymphoma. 63(7). 1660–1668. 15 indexed citations
4.
Motzer, Robert J., Yanfang Liu, Rodolfo F. Perini, Yayan Zhang, & Daniel Yick Chin Heng. (2021). Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.. Journal of Clinical Oncology. 39(6_suppl). TPS372–TPS372. 5 indexed citations
5.
6.
Rischin, Danny, Kevin J. Harrington, Richard Greil, et al.. (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6000–6000. 101 indexed citations
7.
Zinzani, Pier Luigi, Vincent Ribrag, Craig H. Moskowitz, et al.. (2017). Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 130(3). 267–270. 218 indexed citations
8.
Garcia‐Manero, Guillermo, Martin S. Tallman, Giovanni Martinelli, et al.. (2016). Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. Blood. 128(22). 345–345. 46 indexed citations
9.
Zinzani, Pier Luigi, Vincent Ribrag, Craig H. Moskowitz, et al.. (2016). Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial. Blood. 128(22). 619–619. 11 indexed citations
10.
Zhang, Yayan. (2015). Data normalization and clustering for big and small data and an application to clinical trials. Rutgers University Community Repository (Rutgers University). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johannes Andel Breakdown of academic impact, for papers by Yi‐Fang Chang Breakdown of academic impact, for papers by Guillaume Manson Breakdown of academic impact, for papers by Yu‐Jing Zhang Breakdown of academic impact, for papers by Lokanatha Dasappa Breakdown of academic impact, for papers by Yuhua Feng Breakdown of academic impact, for papers by Scott D. Lunin Breakdown of academic impact, for papers by Fernando Hurtado de Mendoza Breakdown of academic impact, for papers by Manuel F. Rosado Breakdown of academic impact, for papers by Yuki Komabayashi
Rankless by CCL
2026